Induction and Maintenance Immunosuppression

Immunosuppression after transplantation is organised into two phases. Induction is intense, short-term suppression given at the time of transplant - when the risk of rejection is highest - often using antibody agents. Maintenance is the lower-intensity, long-term regimen, typically combining a calcineurin inhibitor, an antiproliferative agent, and a corticosteroid, that is continued to keep the graft from being rejected.

Definition

Induction and maintenance immunosuppression is the two-phase strategy of giving intense, short-term immunosuppression at the time of transplantation (induction) followed by a sustained, lower-intensity combination regimen (maintenance) to prevent allograft rejection over the life of the graft.

Scope

This topic covers the strategy that ties the drug classes together: the rationale for time-limited high-intensity induction versus long-term lower-intensity maintenance, the common multi-drug structure of maintenance regimens, and the principle of tailoring intensity to immunologic risk while limiting the cumulative harms of suppression. It is a reference treatment of the strategy and not a protocol or prescribing guidance.

Core questions

• Why is immunosuppression most intense at the time of transplantation?
• What distinguishes the goals of induction from those of maintenance?
• Why do maintenance regimens typically combine drugs from several classes?
• How is the intensity of immunosuppression matched to a recipient's immunologic risk?

Key concepts

• Induction therapy
• Maintenance therapy
• Triple-drug regimen
• Risk stratification (immunologic risk)
• Minimization and withdrawal strategies
• Cumulative immunosuppression and its harms

Mechanisms

Rejection risk is greatest in the early period after transplantation, so induction delivers intense suppression - frequently with depleting or non-depleting antibody agents - to blunt the initial alloimmune response while baseline drugs take effect. As that early risk falls, the regimen transitions to maintenance, usually a combination of a calcineurin inhibitor, an antiproliferative agent, and a corticosteroid, each acting on a different step of the rejection cascade so that lower doses of each can be used. The intensity of both phases is matched to the recipient's immunologic risk, and over time clinicians may minimize or withdraw individual components to reduce the cumulative burden of infection, malignancy, and drug toxicity while keeping rejection risk acceptably low.

Clinical relevance

The induction-maintenance framework explains how the individual drug classes are deployed over time and why immunosuppression is tapered rather than fixed; it underlies the design of transplant regimens and the interpretation of their outcomes. This entry describes the strategy at a conceptual level for reference and is not a basis for selecting regimens, dosing, or tapering in individual patients.

History

Early transplantation relied on a fixed combination of azathioprine and corticosteroids, with antilymphocyte preparations used for severe rejection. The arrival of cyclosporine, then tacrolimus, mycophenolate, mTOR inhibitors, and modern antibody agents allowed regimens to be structured deliberately into an intense induction phase and a tailored maintenance phase. Trials comparing induction agents and maintenance combinations, together with guideline syntheses, established risk-adapted regimens and motivated minimization strategies to limit long-term harm.

Debates

How intense should induction be, and for whom?

Lymphocyte-depleting induction lowers early rejection more than non-depleting induction but increases infection and other risks; matching induction intensity to immunologic risk rather than applying one approach to all recipients remains an area of ongoing judgement.

Seminal works

• halloran-2004
• kdigo-2009

Frequently asked questions

What is the difference between induction and maintenance immunosuppression?

Induction is brief, intense suppression given around the time of transplant when rejection risk is highest, often using antibody agents; maintenance is the long-term, lower-intensity combination regimen continued afterward to keep the graft from being rejected.

Why do maintenance regimens usually use three drugs?

Combining a calcineurin inhibitor, an antiproliferative agent, and a corticosteroid suppresses the rejection response at several different steps, which allows lower doses of each drug and a better balance between efficacy and toxicity.